糠酸莫米松鼻喷剂在儿童腺样体肥大治疗中的作用

The Role of Mometasone Furoate Aqueous Nasal Spray on Adenoidal Hypertrophy in Children

目的探讨糠酸莫米松鼻喷剂在儿童腺样体肥大治疗中临床应用价值。方法对78例腺样体肥大患儿,分成两组:安慰剂组,35例每天用鼻腔冲洗器冲洗鼻腔1次;用药组43例,给予糠酸莫米松鼻喷剂50μg,1次/d。治疗3个月,随访12个月。在治疗前、治疗3个月和治疗后12个月,分别进行鼻声反射检查和症状评分。结果安慰剂组各时间段临床评分和鼻咽部体积无明显改变(P>0.05);用药组在用药后3个月,患儿临床评分为8.25±2.31,鼻咽部体积为20.87 cm3±3.56 cm3,与用药前临床评分10.30±1.51,及鼻咽部的体积15.21 cm3±2.17 cm3相比,具有统计学意义(P<0.01)。在随访12个月,临床评分和鼻咽部体积与治疗前相比有明显好转,具有统计学意义(P<0.01)。结论糠酸莫米松鼻喷剂能够减小肥大腺样体的体积,减轻慢性鼻阻塞的严重程度,为非手术治疗提供了新的途径。

Objective To explore the role of mometasone furoate aqueous nasal spray on adenoidal hypertrophy in children.Methods The 78 children were divided into two groups,one group had 35 children washing their nasal cavity with nasal irrigator once a day,the other one had 43 children provided with mometasone furoate aqueous nasal spray 50 ug once a day.After 3 months,it was followed up for 12 months.They were measured with acoustic rhinometry and symptome score on the 3-month,before and after the treatment.Results There was no difference between periods on symptome score and nasopharynx volume（NPV） in the placebo group（P〉0.05）.In the nasal spray group,after 3 months symptome score was 8.25±2.31 and NPV 20.87 cm3±3.56 cm3.The symptome score is 10.30±1.51 and NPV is 15.21 cm3±2.17 cm3.which has significant difference between them（〈P0.01）.There is significant difference between the follow-up 12 month and pre-treatment on symptome score and NPV（P〈0.01）.Conclusion Mometasone furoate aqueous nasal spray could decrease adenoid size and reduces the severity of chronic nasal obstruction symptoms in children affected by adenoidal hypertrophy,and provide a new nonsurgery way.